Nuvation Bio’s FDA approval of Ibtrozi, a next-generation tyrosine kinase inhibitor for ROS1-positive non-small cell lung cancer, demonstrates clinical efficacy with favorable safety, offering a promising new treatment option in a competitive therapeutic area and potential for substantial market impact.